Error loading player: No playable sources found
2395
Human and Experimental Cholestasis
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AASLD
| METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS |
| EFFECT OF OBETICHOLIC ACID ON APRI SCORE IN PATIENTS AT HIGHER RISK FOR FIBROSIS, AS DETERMINED BY HIGHER BASELINE FIBROSIS-4 SCORE AND LIVER STIFFNESS: SUBANALYSIS OF THE PHASE 3 POISE TRIAL IN PRIMARY BILIARY CHOLANGITIS |
| MULTI-OMIC SEQUENCING REVEALS DISTINCTIVE GENE EXPRESSION AND DNA METHYLATION ALTERATIONS AS POTENTIAL PREDICTORS OF PRIMARY SCLEROSING CHOLANGITIS DEVELOPMENT IN TREATMENT-NAÏVE PAEDIATRIC ULCERATIVE COLITIS |
| METABOLIC BIOMARKERS PREDICT THE OUTCOME OF UDCA TREATMENT ON PBC PATIENTS WITH HIGH ACCURACY |
| PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY |
| FOLIC ACID DEFICIENCY EXACERBATES BILIARY INFLAMMATION IN PRIMARY BILIARY CHOLANGITIS BY PROMOTING CHOLANGIOCYTE SENESCENCE |
Moderators
Indiana University
University of Southern California
Speakers
University of Nevada Las Vegas School of Medicine
Tracks
Related Products
It's Not Over: Viral Hepatitis in the Modern Era
SOCIETY: AASLD
Career Planning for APPs (Hep Associations Committee)
ADDICTION TREATMENT AND HARM REDUCTION IN VIRAL HEPATITIS
